Reported results
- Net loss was $30.7 million, or $(0.25) per share, for the third quarter of 2026.
- Total operating expenses were $32.2 million for the third quarter of 2026.
- Research and development expenses were $24.2 million for the third quarter of 2026.
- General and administrative expenses were $8.0 million for the third quarter of 2026.
- Cash, cash equivalents, and investments as of September 30, 2026, were $139.1 million.
Guidance
- Cash runway expected to mid-2028, including the $139.1 million in cash, cash equivalents, and investments and the $15.0 million CIRM grant.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
